Balanced news tone
News Sentiment
MAZE sentiment intelligence
Maze Therapeutics, Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
News tone and price action are not far from neutral.
81/100 classification confidence.
directly relevant articles
high-authority source matches
-2.2% over one week, +27.1% over four weeks, trend inactive, and near fair-value range.
$MAZE stock is down 10% today. Here's what we see in our data.
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Apr 2026 07:00
- Source
- StockStory
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Nektar’s $325M offering; Maze stock rises; Merck deal rumors; BMS layoffs
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 23 Apr 2026 07:00
- Source
- Endpoints News
Maze Therapeutics Prices Public Offering of 5,540,000 Shares at $23.50 Per Share, Aiming for $150 Million in Gross Proceeds | MAZE Stock News
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Apr 2026 07:00
- Source
- Quiver Quantitative
Abbott is the most oversold healthcare stock as Q1 earnings roll on (XLV:NYSEARCA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 22 Apr 2026 07:00
- Source
- Seeking Alpha
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
Atul Dandekar, CSBO of Maze Therapeutics, sells $220k in Maze stock
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Apr 2026 07:00
- Source
- Investing.com
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
Maze Therapeutics: MZE829 Presses Forward Despite Stock Price Drop (NASDAQ:MAZE)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Mar 2026 07:00
- Source
- Seeking Alpha
After Plunging 30.8% in 4 Weeks, Here's Why the Trend Might Reverse for Maze Therapeutics, Inc. (MAZE)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Mar 2026 07:00
- Source
- Market source
After ph. 2 readout, analysts herald 'best-in-class potential' for Maze kidney candidate as stock plummets
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Mar 2026 07:00
- Source
- Fierce Biotech
Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 18 Mar 2026 07:00
- Source
- Market source
Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Feb 2026 09:53
- Source
- Kavout | AI
Cava Stock Surges 24% After Upbeat Earnings and Strong 2026 Outlook
- Tone
- Positive 82/100
- Event
- Earnings
- Published
- 26 Feb 2026 08:00
- Source
- TIKR.com
Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 25 Feb 2026 08:00
- Source
- TIKR.com
This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 24 Feb 2026 08:00
- Source
- Barron's
Maze Therapeutics Chief Medical Officer Sells 15K Shares As Company's Stock Continues to Surge
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 15 Feb 2026 08:00
- Source
- Market source
UnitedHealth Stock Plummets 20% After Earnings. Why Soft Revenue Isn’t the Only Problem.
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 27 Jan 2026 08:00
- Source
- Barron's
Maze Therapeutics (MAZE) Stock Price, News & Analysis
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Apr 2025 07:17
- Source
- Stock Titan
VRDN Stock Price and Chart — NASDAQ:VRDN
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 Dec 2022 08:00
- Source
- TradingView